.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,987,101

« Back to Dashboard

Claims for Patent: 6,987,101

Title:Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
Abstract:A method for treating premenstrual dysphoric disorder comprises administering a therapeutically effective amount of a gestagen. Optionally, a natural or synthetic estrogen is also administered. In one embodiment, the gestagen and optional estrogen are administered during the luteal phase of the female menstrual cycle, preferably from day 10 to day 28.
Inventor(s): Nashed; Norman (Munchen, DE)
Assignee: Schering Aktiengesellschaft (Berlin, DE)
Application Number:09/619,493
Patent Claims: 1. A method of treating premenstrual dysphoric disorder, comprising administering to a patient in need of such treatment a therapeutically effective amount of a gestagen, which is drospirenone.

2. A method of treating premenstrual dysphoric disorder comprising administering to a patient in need of such treatment a therapeutically effective amount of a gestagen, which is drospirenone, further comprising an estrogen.

3. The method of claim 2, wherein the estrogen is synthetic.

4. The method of claim 3, wherein the estrogen is ethinylestradiol.

5. The method of claim 2, wherein the estrogen is an estrogen sulfamate.

6. The method of claim 2, wherein the estrogen is natural.

7. The method of claim 6, wherein the estrogen is estradiol, estradiol valerate or another estradiol ester.

8. The method of claim 1, wherein the gestagen is administered only during the luteal phase of the female menstrual cycle.

9. The method of claim 8, wherein the gestagen is administered from day 10 to 28 of the menstrual cycle.

10. The method of claim 1, wherein the gestagen administered in an amount of 0.5 mg to less than 5 mg daily.

11. The method of claim 4, wherein the ethinylestradiol is administered in an amount of 0.010 to 0.05 mg daily.

12. The method of claim 7, wherein estradiol is administered in an amount of 1.0 to 3.0 mg daily.

13. The method of claim 3, wherein the gestagen and estrogen are administered together.

14. The method of claim 13, wherein the gestagen and estrogen are administered orally.

15. The method of claim 7, wherein the estrogen is estradiol.

16. The method of claim 10, wherein the daily dose of drospirenone is 1.0 to 4.0 mg.

17. The method of claim 3, wherein the estrogen is an estratrien-3-amidosulfonate.

18. The method of claim 3, wherein the estrogen is a 14a,15a-methylene steriod from the estrane series.

19. The method of claim 2, wherein the gestagen and estrogen are administered continuously.

20. The method of claim 2, wherein the gestagen and estrogen are administered sequentially.

21. The method of claim 2, wherein the gestagen and estrogen are administered cyclically.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc